Get the Stockscreener App
1.19
0.83%
-0.01
After Hours:
1.22
0.03
+2.52%
Pds Biotechnology Corporation stock is traded at $1.19, with a volume of 339.45K.
It is down -0.83% in the last 24 hours and up +1.71% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$1.20
Open:
$1.22
24h Volume:
339.45K
Relative Volume:
0.64
Market Cap:
$54.39M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-1.0171
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
+7.21%
1M Performance:
+1.71%
6M Performance:
-23.72%
1Y Performance:
-63.16%
1-Day Range:
$1.18
$1.25
1-Week Range:
$1.06
$1.32
52-Week Range:
$0.8505
$4.29
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.19 | 54.85M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
Using Python tools to backtest PDS Biotechnology Corporation strategiesLong Setup & Weekly High Return Stock Opportunities - Newser
Smart tools for monitoring PDS Biotechnology Corporation’s price actionWeekly Trade Review & Weekly Watchlist for Hot Stocks - Newser
What the charts say about PDS Biotechnology Corporation today2025 Top Gainers & Low Risk Entry Point Guides - Newser
What institutional flow reveals about PDS Biotechnology Corporation2025 Investor Takeaways & Verified Trade Idea Suggestions - Newser
Market reaction to PDS Biotechnology Corporation’s recent news2025 AllTime Highs & Free Daily Entry Point Trade Alerts - Newser
What does recent volatility data suggest for PDS Biotechnology CorporationPortfolio Value Summary & Accurate Buy Signal Alerts - Newser
Short interest data insights for PDS Biotechnology CorporationJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - Newser
HC Wainwright Lifts Earnings Estimates for PDS Biotechnology - Defense World
Statistical indicators supporting PDS Biotechnology Corporation’s strengthWeekly Trend Recap & Community Trade Idea Sharing - Newser
Evaluating PDS Biotechnology Corporation with trendline analysisEarnings Overview Summary & Stock Portfolio Risk Management - Newser
Applying sector rotation models to PDS Biotechnology CorporationWall Street Watch & Long-Term Capital Growth Ideas - Newser
Can trapped investors hope for a rebound in PDS Biotechnology Corporation2025 Momentum Check & Weekly Chart Analysis and Guides - Newser
Using Ichimoku Cloud for PDS Biotechnology Corporation technicalsJuly 2025 Final Week & Risk Adjusted Buy and Sell Alerts - Newser
Candlestick Signal Suggests Reversal in PDS Biotechnology CorporationJuly 2025 Outlook & Verified Entry Point Signals - metal.it
Is PDS Biotechnology Corporation the Top Chart Pick This WeekQuarterly Risk Review & Fast Entry High Yield Stock Tips - beatles.ru
What makes PDS Biotechnology Corporation stock price move sharplySwing Trade & Fast Gain Stock Tips - Newser
PDS Biotech plans completion of metastatic colorectal cancer cohort enrollment by Q4 2025 amid sustained trial momentum - MSN
PDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2025 Earnings Call Transcript - Insider Monkey
PDS Biotechnology Corporation Sees Spike in Bullish Option FlowJuly 2025 EndofMonth & Technical Pattern Alert System - beatles.ru
Risk adjusted return profile for PDS Biotechnology Corporation analyzedJuly 2025 Setups & Technical Confirmation Trade Alerts - Newser
PDS Biotechnology: Q2 Earnings Snapshot - Greenwich Time
PDS Biotechnology Reports Q2 2025 Financial Results - TipRanks
PDS Biotechnology Q2 2025 Earnings Report - MarketBeat
PDS Biotechnology's Promising Pipeline and Strong Finances Justify Buy Rating - AInvest
Contradictions Uncovered: Insights from the Latest VERSATILE Clinical Trials Earnings Call - AInvest
PDS Biotechnology: Navigating the Crossroads of Innovation and Financial Prudence in a High-Risk Biotech Landscape - AInvest
Blair William & Co. IL Acquires 99,700 Shares of PDS Biotechnology Corporation (NASDAQ:PDSB) - Defense World
Earnings call transcript: PDS Biotech Q2 2025 reports narrower EPS loss, stock rises - Investing.com Australia
Transcript : PDS Biotechnology Corporation, Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Infinity Bio Partners with Austrian Institute of Technology for Expanded Antibody Profiling Access in Europe. - AInvest
PDS Biotechnology Corporation: Analyzing PDSB Stock Trends - investchronicle.com
PDSB Loss Improves as Costs Drop - The Motley Fool
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update - MarketScreener
PDS Biotech's Cancer Drug Hits Key Trial Goal as Q2 Losses Widen to $9.4M - Stock Titan
How to build a dashboard for PDS Biotechnology Corporation stockLong Setup & Risk Adjusted Swing Trade Ideas - Newser
Should you hold or exit PDS Biotechnology Corporation now [Weekly Investment Recap]Low Risk High Reward Trade Ideas - Newser
PDS Biotechnology Corporation Forms Bullish Flag — Upside AheadEntry Zone Strategy for Consistent Profit Shared - sundaytimes.kr
Why PDS Biotechnology Corporation stock attracts strong analyst attentionFree Low Risk Swing Trade Opportunity List - Newser
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):